IN THE PIPELINE
The Immunotherapy Pipeline
Below is a partial list of immunotherapeutic agents under
investigation for the treatment of malignant and non-
malignant hematologic conditions, including monoclonal
antibodies, immune checkpoint inhibitors, and vaccines.
Information was gathered from ClinicalTrials.gov, as well as
the respective drug manufacturers.
For a comprehensive list of agents being evaluated for
these conditions, please consult ClinicalTrials.gov.
CART-BCMA: autologous T cells expressing B-cell maturation
antigen (BCMA)–specific CARs with tandem TCR and 4-1BB
costimulatory domains for the treatment of relapsed and/or
refractory multiple myeloma after autologous hematopoietic
cell transplantation or intensive chemotherapy (phase I)
Dendritic cell/myeloma fusion vaccine: a fusion vaccine for
the treatment of myeloma after AHCT (phase II)
Leukemia JNJ-64007957: an anti-BCMA/anti-CD3 bispecific antibody for
the treatment of relapsed or refractory mult iple myeloma (phase I)
Alemtuzumab: a recombinant humanized anti-CD52
monoclonal antibody for the treatment of B-cell CLL (phase II) SGN-CD352A: an anti-CD352 antibody-drug conjugate for the
treatment of relapsed or refractory multiple myeloma (phase I)
Atezolizumab: a programmed death-ligand 1 (PD-L1) blocking
antibody for the treatment of relapsed or refractory advanced
myelodysplastic syndromes (MDS) or chronic myelomonocytic
leukemia (phase I/II) or high-risk chronic lymphocytic leukemia
(CLL; phase II) Lymphoma
Blinatumomab: an anti-CD19/CD3 bispecific T-cell engager
antibody for the treatment of relapsed or refractory Ph-positive
acute lymphocytic leukemia (ALL; phase II) Axicabtagene ciloleucel: anti-CD19 CAR T cells for the
treatment of refractory DLBCL (phase I/II), relapsed or
refractory indolent non-Hodgkin lymphoma (phase II), or
relapsed or refractory mantle cell lymphoma (phase II)
CC-122: a pleiotropic pathway modifier for the treatment of CLL/
small lymphocytic lymphoma (phase I/II)
Durvalumab: an anti PD-L1 monoclonal antibody for the
treatment of previously untreated, higher-risk MDS or older
patients with acute myeloid leukemia (phase II)
Myeloma
ALT-803: an interleukin-15 superagonist protein complex for the
treatment of relapsed or refractory myeloma (phase I/II)
AMG 420: an anti-BCMA/anti-CD3 bispecific antibody for the
treatment of multiple myeloma (phase I)
AUTO2: anti-BCMA/TACI CAR T cells for the treatment of
relapsed or refractory multiple myeloma (phase I/II)
Avelumab: an anti-PD-L1 antibody for the treatment of diffuse
large B-cell lymphoma (DLBCL; phase III) and Hodgkin
lymphoma (phase I)
UCART019: anti-CD19 CAR T cells for the treatment of B-cell
lymphoma (phase I/II)
Bleeding and Clotting Disorders
BMN 270: a gene therapy using an adeno-associated virus–
factor VIII vector for the treatment of severe hemophilia A
(phase I/II)
Emicizumab: a recombinant, humanized, bispecific monoclonal
antibody for bleeding prophylaxis in children and adolescents
with hemophilia A and factor VIII inhibitors (phase III)
Fitusiran: an RNA interference therapy for the treatment of
hemophilia A or B with or without inhibitors (phase II) ●
BB2121: an anti-BCMA CAR T-cell construct for the treatment
of relapsed or refractory myeloma (phase I)
BMS-986016: an anti-LAG-3 monoclonal antibody for the
treatment of relapsed or refractory B-cell malignancies
(phase I/II)
CART-138: anti-CD138 CAR T cells for the treatment of relapsed
or refractory, CD138-positive myeloma (phase I/II)
October 2017
3